Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
1.
Plant Dis ; 103(6): 1293-1301, 2019 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-30998451

RESUMEN

Epidemiological field studies utilizing disease monitoring, spore trapping, and trap plants were conducted on rabbiteye blueberry (Vaccinium virgatum) between 2014 and 2017 to shed light on the epidemiology of Exobasidium leaf and fruit spot, an emerging disease in the southeastern United States caused by the fungus Exobasidium maculosum. Wash plating of field-collected blueberry tissue from the late dormant season through bud expansion showed that the pathogen overwintered epiphytically on blueberry plants in the field, most likely in its yeast-like conidial stage. Agrichemical applications during the dormant season altered epiphytic populations of the pathogen, which correlated directly with leaf spot incidence later in the spring. Disease monitoring of field plants and weekly exposure of potted trap plants revealed that young leaves at the mouse-ear stage were most susceptible to infection, that disease incidence on leaves progressed monocyclically, and that infection periods were associated with rainfall variables such as the number of days per week with ≥1.0 mm of rain or cumulative weekly rainfall. Weekly spore trapping with an Andersen sampler showed that airborne inoculum was detected only after sporulating leaf lesions producing basidiospores were present in the field, suggesting that the primary inoculum is not airborne. The first symptoms on young, green fruit were observed soon after petal fall (requiring removal of the waxy fruit layer to visualize lesions), and visible disease progress on fruit was delayed by 1 to 3 weeks relative to that on leaves. Fruit infection of field plants and trap plants occurred before airborne propagules were detected by spore trapping and before sporulating leaf lesions were present in the field. Hence, this study showed that fruit infections are initiated by the same initial inoculum as leaf infections but it was not possible to conclusively exclude the possibility of a contribution of basidiospore inoculum from leaf lesions to disease progress on later developing fruit. This is one of only a few studies addressing the epidemiology and disease cycle of an Exobasidium sp. in a pathosystem where artificial inoculation has not been possible to date.


Asunto(s)
Arándanos Azules (Planta) , Frutas , Hojas de la Planta , Arándanos Azules (Planta)/microbiología , Epidemiología , Frutas/microbiología , Enfermedades de las Plantas/microbiología , Enfermedades de las Plantas/prevención & control , Hojas de la Planta/microbiología , Sudeste de Estados Unidos
2.
Epidemiol Infect ; 147: e87, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30869059

RESUMEN

To determine the burden of skin and soft tissue infections (SSTI), the nature of antimicrobial prescribing and factors contributing to inappropriate prescribing for SSTIs in Australian aged care facilities, SSTI and antimicrobial prescribing data were collected via a standardised national survey. The proportion of residents prescribed ⩾1 antimicrobial for presumed SSTI and the proportion whose infections met McGeer et al. surveillance definitions were determined. Antimicrobial choice was compared to national prescribing guidelines and prescription duration analysed using a negative binomial mixed-effects regression model. Of 12 319 surveyed residents, 452 (3.7%) were prescribed an antimicrobial for a SSTI and 29% of these residents had confirmed infection. Topical clotrimazole was most frequently prescribed, often for unspecified indications. Where an indication was documented, antimicrobial choice was generally aligned with recommendations. Duration of prescribing (in days) was associated with use of an agent for prophylaxis (rate ratio (RR) 1.63, 95% confidence interval (CI) 1.08-2.52), PRN orders (RR 2.10, 95% CI 1.42-3.11) and prescription of a topical agent (RR 1.47, 95% CI 1.08-2.02), while documentation of a review or stop date was associated with reduced duration of prescribing (RR 0.33, 95% CI 0.25-0.43). Antimicrobial prescribing for SSTI is frequent in aged care facilities in Australia. Methods to enhance appropriate prescribing, including clinician documentation, are required.


Asunto(s)
Antibacterianos/administración & dosificación , Prescripción Inadecuada/estadística & datos numéricos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Enfermedades Cutáneas Infecciosas/epidemiología , Infecciones de los Tejidos Blandos/epidemiología , Anciano , Anciano de 80 o más Años , Australia/epidemiología , Femenino , Humanos , Masculino , Enfermedades Cutáneas Infecciosas/microbiología , Infecciones de los Tejidos Blandos/microbiología
3.
Mucosal Immunol ; 9(3): 669-76, 2016 05.
Artículo en Inglés | MEDLINE | ID: mdl-26376365

RESUMEN

Secretory leukocyte protease inhibitor (SLPI) is an important respiratory tract host defense protein, which is proteolytically inactivated by excessive neutrophil elastase (NE) during chronic Pseudomonas infection in the cystic fibrosis (CF) lung. We generated two putative NE-resistant variants of SLPI by site-directed mutagenesis, SLPI-A16G and SLPI-S15G-A16G, with a view to improving SLPI's proteolytic stability. Both variants showed enhanced resistance to degradation in the presence of excess NE as well as CF patient sputum compared with SLPI-wild type (SLPI-WT). The ability of both variants to bind bacterial lipopolysaccharides and interact with nuclear factor-κB DNA binding sites was also preserved. Finally, we demonstrate increased anti-inflammatory activity of the SLPI-A16G protein compared with SLPI-WT in a murine model of pulmonary Pseudomonas infection. This study demonstrates the increased stability of these SLPI variants compared with SLPI-WT and their therapeutic potential as a putative anti-inflammatory treatment for CF lung disease.


Asunto(s)
Fibrosis Quística/inmunología , Elastasa de Leucocito/metabolismo , Pulmón/inmunología , Infecciones por Pseudomonas/inmunología , Pseudomonas aeruginosa/inmunología , Inhibidor Secretorio de Peptidasas Leucocitarias/metabolismo , Animales , Células Cultivadas , Enfermedad Crónica , Fibrosis Quística/complicaciones , Modelos Animales de Enfermedad , Humanos , Inmunidad Innata , Pulmón/microbiología , Ratones , Ratones Endogámicos C57BL , Mutagénesis Sitio-Dirigida , Mutación/genética , Infiltración Neutrófila , Proteolisis , Infecciones por Pseudomonas/complicaciones , Inhibidor Secretorio de Peptidasas Leucocitarias/genética
4.
Intern Med J ; 45(2): 148-55, 2015 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-25404003

RESUMEN

BACKGROUND: There are limited clinical data on enteric fever in the Pacific and New Zealand (NZ) compared with the Indian subcontinent (ISC) and South-East Asia (SEA). Our objective was to describe enteric fever in Auckland - a large Pacific city, focusing on disease acquired in these regions. METHODS: We reviewed enteric fever cases hospitalised in Auckland from January 2005 to December 2010. RESULTS: Microbiologically confirmed EF was identified in 162 patients. Travel regions: Pacific, 40 cases (25%) (Samoa, 38; Fiji, two), ISC, 72 (44%), SEA, seven (4%), other, three (2%), no travel, 40 (25%). Enteric fever rates for Auckland resident travellers were: India 50.3/100 000; Samoa 19.7/100 000.All Pacific cases were Salmonella Typhi. Of local isolates (without travel history), 38 were S. Typhi (36 fully susceptible, one multi-drug resistant (MDR) + nalidixic acid resistant (NAR), one unknown) and two S. Paratyphi (both NAR). Of non-Pacific travel, 56/82 (69%) isolates were S. Typhi, the remainder S. Paratyphi (15 isolates were fully susceptible, only 1% were MDR). Significant associations of serotype and antibiotic resistance with different travel regions and similarity of phage types (local and Pacific) were observed. Headache, vomiting and acute kidney injuries were more frequent with Pacific travel, while abdominal distension and cholecystitis with local disease. Shorter duration of treatment in the Pacific group was seen despite length of stay in hospital not being reduced. Local cases were associated with longer hospital admissions. CONCLUSIONS: One half of cases in Auckland are acquired either from Pacific or locally. Similarities mean that disease acquired locally is likely of Pacific origin.


Asunto(s)
Brotes de Enfermedades , Salmonella paratyphi A/aislamiento & purificación , Salmonella typhi/aislamiento & purificación , Fiebre Tifoidea/epidemiología , Fiebre Tifoidea/microbiología , Adolescente , Adulto , Distribución por Edad , Análisis de Varianza , Antibacterianos/uso terapéutico , Niño , Preescolar , Estudios de Cohortes , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Incidencia , Lactante , Masculino , Persona de Mediana Edad , Nueva Zelanda/epidemiología , Islas del Pacífico/epidemiología , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Distribución por Sexo , Fiebre Tifoidea/tratamiento farmacológico , Población Urbana , Adulto Joven
5.
Intern Med J ; 44(12a): 1180-7, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25070720

RESUMEN

BACKGROUND: In Australia, antimicrobial stewardship programmes are a compulsory component of hospital accreditation. Good documentation around anti-microbial prescribing aids communication and can improve prescribing practice in environments with multiple decision makers. AIM: This study aims to develop and implement an intervention to improve antimicrobial prescribing practice in a 24-bed intensive care unit in a tertiary referral adult hospital. METHODS: We conducted a four-phase (observation, reflection, implementation, evaluation) prospective collaborative before-after quality improvement study. Baseline audits and surveys of antimicrobial prescribing practices identified barriers to and enablers of good prescribing practice. A customised intervention was then implemented over 6 weeks and included a yellow medication record sticker, quarterly education sessions and intensive care unit-specific empiric antimicrobial prescribing guidelines. Post-implementation, the effects were monitored by serial antimicrobial prescribing audits for 1 year. The primary outcomes were clear documentation of the start date, the planned stop date or review date and the indication for an antibiotic. These were all considered the 'minimum standards' for an antimicrobial prescription on the medication record. RESULTS: Documentation of minimum standards specifically addressed by the sticker improved (start date (72% to 90%, P < 0.001), stop date (16% to 63%, P < 0.001), antimicrobial indication documented on medication chart (58% to 83%, P < 0.01)). Overall, adherence to all three minimum standards (start date, stop date and indication) improved from 41/306 (13%) to 306/492 (63%) (P < 0.001). One-year post-implementation, the yellow sticker had become embedded into daily practice. CONCLUSION: A systematic approach to quality improvement combined with the implementation of a tailored, multi-faceted intervention can improve antimicrobial prescribing practices.


Asunto(s)
Antibacterianos/administración & dosificación , Cuidados Críticos/métodos , Cuidados Críticos/normas , Adhesión a Directriz , Pautas de la Práctica en Medicina/normas , Mejoramiento de la Calidad , Australia/epidemiología , Auditoría Clínica , Conducta Cooperativa , Encuestas de Atención de la Salud , Conocimientos, Actitudes y Práctica en Salud , Humanos , Unidades de Cuidados Intensivos , Estudios Prospectivos
6.
Cell Microbiol ; 15(12): 2080-92, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23870035

RESUMEN

Helicobacter pylori establishes a chronic lifelong infection in the human gastric mucosa, which may lead to peptic ulcer disease or gastric adenocarcinoma. The human beta-defensins (hßDs) are antimicrobial peptides, hßD1 being constitutively expressed in the human stomach. We hypothesized that H. pylori may persist, in part, by downregulating gastric hßD1 expression. We measured hßD1 and hßD2 expression in vivo in relation to the presence, density and severity of H. pylori infection, investigated differential effects of H. pylori virulence factors, and studied underlying signalling mechanisms in vitro. Significantly lower hßD1 and higher hßD2 mRNA and protein concentrations were present in gastric biopsies from infected patients. Those patients with higher-level bacterial colonization and inflammation had significantly lower hßD1 expression, but there were no differences in hßD2. H. pylori infection of human gastric epithelial cell lines also downregulated hßD1. Using wild-type strains and isogenic mutants, we showed that a functional cag pathogenicity island-encoded type IV secretion system induced this downregulation. Treatment with chemical inhibitors or siRNA revealed that H. pylori usurped NF-κB signalling to modulate hßD1 expression. These data indicate that H. pylori downregulates hßD1 expression via NF-κB signalling, and suggest that this may promote bacterial survival and persistence in the gastric niche.


Asunto(s)
Infecciones por Helicobacter/inmunología , Helicobacter pylori/metabolismo , Evasión Inmune/inmunología , beta-Defensinas/biosíntesis , Sistemas de Secreción Bacterianos , Línea Celular , Regulación hacia Abajo , Mucosa Gástrica/inmunología , Mucosa Gástrica/metabolismo , Mucosa Gástrica/microbiología , Infecciones por Helicobacter/metabolismo , Infecciones por Helicobacter/microbiología , Helicobacter pylori/inmunología , Helicobacter pylori/patogenicidad , Humanos , Proteína Quinasa 1 Activada por Mitógenos/genética , Subunidad p50 de NF-kappa B/genética , Interferencia de ARN , ARN Mensajero/biosíntesis , ARN Interferente Pequeño , Transducción de Señal , Estómago/inmunología , Estómago/microbiología , Factor de Transcripción ReIA/genética , beta-Defensinas/genética
7.
Clin Exp Immunol ; 173(1): 84-91, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-23607659

RESUMEN

Anthrax is a toxin-mediated disease, the lethal effects of which are initiated by the binding of protective antigen (PA) with one of three reported cell surface toxin receptors (ANTXR). Receptor binding has been shown to influence host susceptibility to the toxins. Despite this crucial role for ANTXR in the outcome of disease, and the reported immunomodulatory consequence of the anthrax toxins during infection, little is known about ANTXR expression on human leucocytes. We characterized the expression levels of ANTXR1 (TEM8) on human leucocytes using flow cytometry. In order to assess the effect of prior toxin exposure on ANTXR1 expression levels, leucocytes from individuals with no known exposure, those exposed to toxin through vaccination and convalescent individuals were analysed. Donors could be defined as either 'low' or 'high' expressers based on the percentage of ANTXR1-positive monocytes detected. Previous exposure to toxins appears to modulate ANTXR1 expression, exposure through active infection being associated with lower receptor expression. A significant correlation between low receptor expression and high anthrax toxin-specific interferon (IFN)-γ responses was observed in previously infected individuals. We propose that there is an attenuation of ANTXR1 expression post-infection which may be a protective mechanism that has evolved to prevent reinfection.


Asunto(s)
Carbunco/sangre , Antígenos Bacterianos/farmacología , Toxinas Bacterianas/farmacología , Leucocitos Mononucleares/efectos de los fármacos , Proteínas de Neoplasias/biosíntesis , Receptores de Superficie Celular/biosíntesis , Enfermedades Cutáneas Bacterianas/sangre , Carbunco/genética , Vacunas contra el Carbunco/farmacología , Antígenos Bacterianos/metabolismo , Estudios de Cohortes , Convalecencia , Citometría de Flujo , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Inmunización Secundaria , Interferón gamma/biosíntesis , Interferón gamma/genética , Leucocitos Mononucleares/metabolismo , Proteínas de Microfilamentos , Proteínas de Neoplasias/genética , Receptores de Superficie Celular/genética , Enfermedades Cutáneas Bacterianas/genética , Turquía , Reino Unido , Vacunación
8.
Intern Med J ; 37(5): 290-4, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17504275

RESUMEN

BACKGROUND: The aims of this study were to determine the clinical characteristics on arrival and the subsequent clinical outcome of HIV-infected UN quota refugees who settled in New Zealand during the last 11 years and to estimate their rate of HIV transmission. METHODS: A population study was conducted. Data were provided by the Mangere Refugee Resettlement Centre, the infectious disease physicians caring for the subjects, the New Zealand AIDS Epidemiology Group and laboratories carrying out HIV viral load assays. RESULTS: One hundred of 7732 (1.3%) UN quota refugees were HIV positive; mean age 30 years, 56% were men, median initial CD4 count was 320 (range 20-1358). HIV infection was most commonly acquired by heterosexual intercourse (74%). The median follow up was 5.0 years (range 1 month to 9.7 years). Five died and 15 subjects had 16 AIDS-defining illnesses, most commonly tuberculosis (n = 10). Sixty subjects commenced highly active antiretroviral therapy of whom 36/59 (61%) had an undetectable HIV viral load after 1 year of treatment. None of the six children born to HIV-infected women in New Zealand were infected. There were two known cases of horizontal transmission of HIV infection. CONCLUSION: Although HIV-infected quota refugees often have to overcome severe social, cultural and financial handicaps, their clinical outcome is generally very good, with response rates to highly active antiretroviral therapy that are similar to other patient groups. Furthermore, they have not been a significant source of transmission of HIV infection after resettlement in New Zealand.


Asunto(s)
Emigración e Inmigración , Infecciones por VIH/epidemiología , Infecciones por VIH/terapia , Refugiados , Adolescente , Adulto , Fármacos Anti-VIH/uso terapéutico , Niño , Preescolar , Comorbilidad , Femenino , Infecciones por VIH/transmisión , Humanos , Masculino , Auditoría Médica , Persona de Mediana Edad , Nueva Zelanda , Estudios Retrospectivos , Resultado del Tratamiento
9.
J Helminthol ; 77(1): 27-31, 2003 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12590661

RESUMEN

It has previously been postulated that L-arginine emitted by penetrating Schistosoma mansoni cercariae serves as an intraspecific signal guiding other cercariae to the penetration site. It was suggested that penetrating in groups offers a selective advantage. If this hypothesis is correct and group penetration at one site on the host offers an advantage, it would follow that at such a site, successive groups of cercariae would be able to penetrate skin in either greater numbers or at a faster rate. This prediction was tested by the use of an in vitro model of cercarial penetration based on the Franz cell and using human skin. It was demonstrated that there was no increase in the percentage of cercariae able to penetrate the skin with subsequent exposures. Consequently, it seems unlikely that the release of L-arginine by cercariae during penetration could have evolved as a specific orientation system based on a selective advantage offered by group penetration.


Asunto(s)
Schistosoma mansoni/fisiología , Piel/parasitología , Animales , Arginina/metabolismo , Humanos , Larva , Parasitología/métodos , Schistosoma mansoni/metabolismo
10.
J Parasitol ; 88(2): 399-402, 2002 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-12054019

RESUMEN

One approach to the prevention of schistosomiasis is the use of topical formulations to inhibit cercarial penetration of skin. A number of formulations containing either cercaricidal ingredients or components designed to inhibit penetration have been studied, but with variable results. Such studies have rarely considered the persistence of inhibitory effects through time, and to date, there have been no systematic investigations of barrier formulations. The aim of this study was to use Franz cells to investigate the effect of such barrier creams on the penetration of S. mansoni cercariae into human skin. The results show that a single application of a barrier cream based on dimethicone offers a high level of protection against penetration that is sustained for at least 48 hr.


Asunto(s)
Schistosoma mansoni/crecimiento & desarrollo , Esquistosomiasis mansoni/prevención & control , Simeticona/farmacología , Piel/parasitología , Administración Tópica , Animales , Emolientes/administración & dosificación , Emolientes/farmacología , Femenino , Humanos , Técnicas In Vitro , Schistosoma mansoni/metabolismo , Simeticona/administración & dosificación
11.
N Z Med J ; 113(1104): 58-62, 2000 Feb 25.
Artículo en Inglés | MEDLINE | ID: mdl-10777227

RESUMEN

In children, pneumonia must be differentiated from bronchiolitis and asthma. Pneumonia is the only one of these three conditions for which antibiotics are indicated. Clinical signs are more useful than radiological or laboratory investigations for differentiating pneumonia from bronchiolitis and asthma. A child has pneumonia if s/he has tachypnoea or indrawing and is not wheezing. The child's age and the severity of the illness episode predict the aetiology of the pneumonia. The majority of children with community-acquired pneumonia can be managed in primary care. The antibiotic of choice for children < or = 5 years of age is oral amoxycillin and for older children and adolescents is oral erythromycin. Antibiotics will not prevent pneumonia in a child with an upper respiratory tract infection. Up to 80% of adults with pneumonia can be managed as outpatients. Indicators of morbidity and mortality from pneumonia are well described. Clinical features and radiology do not reliably predict the causative agent in adults with pneumonia, thus initial treatment is empirical. Streptococcus pneumoniae is the most common cause of pneumonia in all studies. The initial antibiotic treatment should be active against this organism. Penicillin oramoxycillin or erythromycin are all suitable. Erythromycin has the advantage of being active against Mycoplasma pneumoniae and Legionella species. Follow-up of patients is important to decide whether they are responding to the empirical treatment.


Asunto(s)
Neumonía/terapia , Adolescente , Adulto , Factores de Edad , Anciano , Algoritmos , Antibacterianos/uso terapéutico , Niño , Preescolar , Infecciones Comunitarias Adquiridas/diagnóstico , Infecciones Comunitarias Adquiridas/etiología , Infecciones Comunitarias Adquiridas/terapia , Humanos , Lactante , Recién Nacido , Vacunas contra la Influenza , Neumonía/diagnóstico , Neumonía/etiología
13.
Clin Infect Dis ; 23(3): 624-7, 1996 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-8879789

RESUMEN

To better understand the natural history, management, and outcome of pneumothoraces in HIV-infected patients, we reviewed hospital charts and chest radiographs of HIV-infected adults discharged from the University of Maryland Medical Center over a 6-year period. Sixty pneumothoraces occurred in 39 patients. Twenty-three pneumothoraces resulted from trauma and 37 were spontaneous. Thirty-two (86%) of the spontaneous pneumothoraces occurred in patients with Pneumocystis carinii pneumonia (PCP). Eight percent of the traumatic pneumothoraces in patients who did not have PCP resolved. Patients who had pneumothorax as well as PCP were more difficult to manage and had a poorer outcome (50% mortality) than those who did not have PCP (25% mortality).


Asunto(s)
Infecciones por VIH/complicaciones , Neumotórax , Adulto , Femenino , Humanos , Masculino , Neumonía por Pneumocystis/complicaciones , Neumotórax/etiología , Neumotórax/terapia , Factores de Riesgo
15.
J Antimicrob Chemother ; 36(1): 259-63, 1995 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8537277

RESUMEN

We compared 40 patients taking lomefloxacin 400 mg once daily for 5 days in a double blind trial with 44 placebo takers with proven community acquired bacterial diarrhoea (85% due to Campylobacter spp.). Lomefloxacin eradicated Campylobacter spp. in 75% but did not alter clinical outcome. Twenty-eight per cent of the campylobacter isolates developed resistance. Thirty-three per cent developed side-effects. Lomefloxacin is not recommended for community-acquired bacterial diarrhoea when Campylobacter spp. predominate.


Asunto(s)
Antiinfecciosos/uso terapéutico , Infecciones Comunitarias Adquiridas/tratamiento farmacológico , Diarrea/tratamiento farmacológico , Fluoroquinolonas , Quinolonas/uso terapéutico , Adulto , Antiinfecciosos/efectos adversos , Antiinfecciosos/farmacología , Campylobacter/efectos de los fármacos , Infecciones por Campylobacter/tratamiento farmacológico , Infecciones por Campylobacter/microbiología , Infecciones Comunitarias Adquiridas/microbiología , Diarrea/microbiología , Método Doble Ciego , Farmacorresistencia Microbiana , Heces/citología , Heces/microbiología , Femenino , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Quinolonas/efectos adversos , Quinolonas/farmacología
16.
Clin Infect Dis ; 15(2): 321-4, 1992 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-1520766

RESUMEN

Two cases of endocarditis caused by Neisseria mucosa are reported, and the literature on N. mucosa endocarditis is reviewed. N. mucosa is a rare but serious cause of endocarditis that is associated with a high rate of embolic complications and high mortality and is not always highly sensitive to benzylpenicillin. Most patients with N. mucosa endocarditis have been treated with combined therapy with penicillin and an aminoglycoside, although the optimal regimen has not been defined.


Asunto(s)
Endocarditis Bacteriana/microbiología , Neisseria , Infecciones por Neisseriaceae/microbiología , Adulto , Aminoglicósidos , Antibacterianos/uso terapéutico , Quimioterapia Combinada/uso terapéutico , Endocarditis Bacteriana/tratamiento farmacológico , Femenino , Humanos , Persona de Mediana Edad , Neisseria/efectos de los fármacos , Neisseria/aislamiento & purificación , Infecciones por Neisseriaceae/tratamiento farmacológico , Penicilinas/uso terapéutico
17.
N Z Med J ; 104(906): 57-9, 1991 Feb 27.
Artículo en Inglés | MEDLINE | ID: mdl-2020443

RESUMEN

Twenty-six patients with cryptococcal meningitis were seen in Auckland between 1969 and 1989. The incidence of cryptococcal meningitis in Auckland residents was 0.12 cases/100,000/year. Ten (38%) of the patients were Maori or Pacific Island Polynesians. Nineteen (73%) had a predisposing cause, including immunosuppressive therapy in nine and the acquired immunodeficiency syndrome (AIDS) in seven. The most common presenting syndrome was a subacute or chronic meningitis. Other clinical syndromes included a slowly progressive ataxia, polyradiculopathy, and headache with vomiting. In two patients, the symptoms of meningitis were overshadowed by those of systemic cryptococcal infection. Delay in making the diagnosis was common. The most sensitive method for diagnosing cryptococcal meningitis was the cerebrospinal fluid cryptococcal antigen test. Antifungal therapy cured 17 of the 25 (68%) treated patients overall, 15 of the 19 (79%) without AIDS and six of the seven with no underlying disease.


Asunto(s)
Criptococosis/epidemiología , Cryptococcus neoformans , Meningitis/epidemiología , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida/epidemiología , Adolescente , Adulto , Anciano , Antifúngicos/uso terapéutico , Criptococosis/líquido cefalorraquídeo , Criptococosis/complicaciones , Criptococosis/tratamiento farmacológico , Femenino , Estudios de Seguimiento , Humanos , Tolerancia Inmunológica , Incidencia , Masculino , Meningitis/líquido cefalorraquídeo , Meningitis/tratamiento farmacológico , Meningitis/etiología , Persona de Mediana Edad , Nueva Zelanda/epidemiología , Estudios Retrospectivos
18.
N Z Med J ; 102(876): 496-8, 1989 Sep 27.
Artículo en Inglés | MEDLINE | ID: mdl-2797573

RESUMEN

We have reviewed admission data, some diagnostic tests, treatment and outcome of 31 male homosexual patients infected with the human immunodeficiency virus with 37 consecutive episodes of presumptive Pneumocystis carinii pneumonia treated at the infectious disease unit, Auckland Hospital, between 1985 and 30 June 1988. The median age was 39 years. Eight episodes were proven Pneumocystis carinii pneumonia, 18 satisfied Centres for Disease Control criteria for presumptive Pneumocystis carinii pneumonia and 11 lacked one Centres for Disease Control criterion. Patients began intravenous or oral cotrimoxazole in 32 episodes, initially 20 mg/k/d of trimethoprim component, but since early 1988 10 mg/k/d. In nine episodes treatment was changed to intravenous pentamidine because of side effects or failure to respond while five received pentamidine as their only drug. Cotrimoxazole caused side effects in 20 of 32 episodes (rash in 11) and pentamidine in 10 of 14 (renal impairment in nine). Two patients died (ie, a 5% mortality for all 37 episodes or 8% for 26 proven and Centres for Disease Control presumptive episodes). Median hospital stay for survivors was 11 days. Fourteen other patients have subsequently died a median eight months after the initial episode. Pneumocystis carinii pneumonia is an important infection in patients infected with the human immunodeficiency virus.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/complicaciones , Neumonía por Pneumocystis/etiología , Síndrome de Inmunodeficiencia Adquirida/epidemiología , Adulto , Broncoscopía , Combinación de Medicamentos/uso terapéutico , Estudios de Seguimiento , Homosexualidad , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Nueva Zelanda/epidemiología , Pentamidina/efectos adversos , Pentamidina/uso terapéutico , Neumonía por Pneumocystis/complicaciones , Neumonía por Pneumocystis/diagnóstico , Neumonía por Pneumocystis/tratamiento farmacológico , Neumonía por Pneumocystis/epidemiología , Neumonía por Pneumocystis/mortalidad , Pirimetamina/uso terapéutico , Recurrencia , Estudios Retrospectivos , Sulfadoxina/uso terapéutico , Factores de Tiempo , Combinación Trimetoprim y Sulfametoxazol/efectos adversos , Combinación Trimetoprim y Sulfametoxazol/uso terapéutico , Zidovudina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA